LIN vs VRDN · P/E 34, rev $18.07B vs rev $425.0K
Linde plc Ordinary Shares (LIN) versus Viridian Therapeutics Inc (VRDN) — a side-by-side from cached financials, not a winner call.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Viridian Therapeutics Inc (VRDN) is a biotechnology company listed on US.
Latest reported LIN revenue for 2026-06-30 was $18.07B. Net income was $3.79B. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Latest reported VRDN revenue for 2026-06-30 was $425.0K. Net income was -$232.0M. VRDN currently screens at market cap $1.39B.
LIN currently screens at market cap $223.87B and trailing P/E 34.5. VRDN currently screens at market cap $1.39B.
Not investment advice. Open the LIN and VRDN stock pages for the full models.
Not investment advice.